Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer | Zendy

Eugene J. Koay | Zendy; Matthew H. G. Katz | Zendy; Huamin Wang | Zendy; Xuemei Wang | Zendy; Laura Prakash | Zendy; Milind Javle | Zendy; Rachna T. Shroff | Zendy; David R. Fogelman | Zendy; Santiago Avila | Zendy; Mohamed Zaid | Zendy; Dalia Elganainy | Zendy; YeonJu Lee | Zendy; Christopher H. Crane | Zendy; Sunil Krishnan | Zendy; Prajnan Das | Zendy; Jason B. Fleming | Zendy; Jeffrey E. Lee | Zendy; Eric P. Tamm | Zendy; Priya Bhosale | Zendy; Jeffrey H. Lee | Zendy; Brian Weston | Zendy; Anirban Maitra | Zendy; Robert A. Wolff | Zendy; Gauri R. Varadhachary | Zendy

Open Access

Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer

Author(s) -

Eugene J. Koay,

Matthew H. G. Katz,

Huamin Wang,

Xuemei Wang,

Laura Prakash,

Milind Javle,

Rachna T. Shroff,

David R. Fogelman,

Santiago Avila,

Mohamed Zaid,

Dalia Elganainy,

YeonJu Lee,

Christopher H. Crane,

Sunil Krishnan,

Prajnan Das,

Jason B. Fleming,

Jeffrey E. Lee,

Eric P. Tamm,

Priya Bhosale,

Jeffrey H. Lee,

Brian Weston,

Anirban Maitra,

Robert A. Wolff,

Gauri R. Varadhachary

Publication year - 2019

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.19.00001

Subject(s) - folfirinox , medicine , oxaliplatin , irinotecan , gemcitabine , pancreatectomy , pancreatic cancer , prospective cohort study , biomarker , hazard ratio , colorectal cancer , adenocarcinoma , radiology , gastroenterology , cancer , oncology , pancreas , confidence interval , biochemistry , chemistry

Effective preoperative regimens and biomarkers for pancreatic ductal adenocarcinoma (PDAC) are lacking. We prospectively evaluated fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX)-based treatment and imaging-based biomarkers for borderline resectable PDAC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research